Rapid Blood Infection Test Fails to Improve Survival

Why It Matters

The findings temper expectations that faster diagnostics automatically translate into better patient outcomes, underscoring the need for integrated clinical pathways and stewardship to realize the promise of rapid testing in high‑resistance settings.

Key Takeaways

• Rapid susceptibility test cut result time to ~7.5 h vs 44 h
• No difference in 30‑day mortality between rapid and standard groups
• Faster antibiotic adjustments observed but did not improve survival
• Carbapenem‑resistant infections showed fewer day‑30 hospitalizations with rapid testing
• Two‑thirds of participants already received effective antibiotics at randomization

Pulse Analysis

Gram‑negative bloodstream infections, driven largely by Escherichia coli, remain a leading cause of sepsis worldwide, especially in low‑ and middle‑income regions where resistance rates are high. Clinicians have long hoped that rapid phenotypic susceptibility testing could shorten the diagnostic window, allowing earlier pathogen‑directed therapy, reducing unnecessary broad‑spectrum antibiotic use, and ultimately lowering mortality. Observational studies have painted an optimistic picture, linking faster identification to shorter hospital stays and improved outcomes, but those settings often featured low resistance prevalence and well‑resourced laboratories.

The JAMA‑published trial enrolled 850 patients in the primary analysis across seven centers in four high‑resistance countries. Participants received either rapid testing directly from positive blood cultures plus standard testing, or standard sub‑culture testing alone, with antimicrobial‑stewardship teams reviewing all results. While the rapid arm achieved a dramatic reduction in time to susceptibility data—approximately 7.5 hours versus 44 hours—the primary clinical endpoints, including 30‑day mortality, length of stay, and ICU admission, showed no meaningful differences. The only measurable clinical advantage was a modest acceleration of antibiotic escalation or de‑escalation, which did not translate into survival benefits.

These results signal that speed alone is insufficient to improve outcomes when a large proportion of patients are already on effective therapy at enrollment, or when access to optimal antibiotics is limited. Hospitals should focus on coupling rapid diagnostics with robust stewardship protocols, ensuring that actionable results reach clinicians promptly and that therapeutic options are available. Future research may need to target subpopulations—such as those with carbapenem‑resistant organisms—where rapid data could have a more pronounced impact, and to explore cost‑effectiveness in resource‑constrained settings. The study reinforces the complexity of translating laboratory innovation into bedside advantage.